Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (NCT05071716)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
🩺 Plain-English Summary (8th-Grade Level)
Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
Who can join: Review the eligibility criteria below.
Location: Bausch Site 182 — Dothan, Alabama
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (150 Sites)
Showing the first 25 of 150 sites.
- Bausch Site 182 — Dothan, Alabama
- Bausch Site 129 — Chandler, Arizona
- Bausch Site 103 — Peoria, Arizona
- Bausch Site 180 — Phoenix, Arizona
- Bausch Site 153 — Phoenix, Arizona
- Bausch Site 248 — Tempe, Arizona
- Bausch Site 222 — Tucson, Arizona
- Bausch Site 150 — Little Rock, Arkansas
- Bausch Site 164 — Bakersfield, California
- Bausch Site 196 — Chula Vista, California
- Bausch Site 226 — Chula Vista, California
- Bausch Site 174 — Escondido, California
- Bausch Site 163 — Fresno, California
- Bausch Site 242 — Garden Grove, California
- Bausch Site 115 — La Jolla, California
- Bausch Site 141 — Lancaster, California
- Bausch Site 140 — Los Angeles, California
- Bausch Site 189 — Los Angeles, California
- Bausch Site 227 — Orange, California
- Bausch Site 199 — Pasadena, California
- Bausch Site 119 — Redwood City, California
- Bausch Site 102 — Rialto, California
- Bausch Site 177 — San Diego, California
- Bausch Site 171 — San Francisco, California
- Bausch Site 214 — San Jose, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatic Encephalopathy
- Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis — Homewood, Alabama
- Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy — Boston, Massachusetts
- Revealing Engagement Patterns Among Hepatic Encephalopathy Patients — San Francisco, California
- Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy — Newark, New Jersey
- Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) — West Haven, Connecticut
Explore by condition: All Hepatic Encephalopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.